
March 13 (Reuters) - Sutro Biopharma Inc STRO.O:
SUTRO BIOPHARMA ANNOUNCES STRATEGIC PORTFOLIO REVIEW RESULTING IN THE PRIORITIZATION OF ITS NEXT-GENERATION ADC PIPELINE
SUTRO BIOPHARMA INC - INTENDS TO EXIT ITS INTERNAL GMP MANUFACTURING FACILITY BY YEAR-END
SUTRO BIOPHARMA INC - JANE CHUNG, PRESIDENT AND COO, TO SUCCEED BILL NEWELL AS CEO AND BOARD DIRECTOR
SUTRO BIOPHARMA INC - WILL REDUCE ITS ORGANIZATIONAL HEADCOUNT BY NEARLY 50 PERCENT
SUTRO BIOPHARMA INC - CASH PAYMENTS ASSOCIATED WITH RESTRUCTURING ARE ESTIMATED TO BE $40 TO $45 MILLION